SequelSEC

ArriVent BioPharma, Inc. AVBP

Pharmaceutical Preparations · CIK 0001868279 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$177.53M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

ArriVent BioPharma, Inc. (AVBP) reported net income of -$166.31M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from ArriVent BioPharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ArriVent BioPharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$177.53M-$94.31M-$74.59M
Net income-$166.31M-$80.49M-$69.33M
Research & development$153.35M$79.00M$64.88M
Weighted-average diluted sharesshares 38.46Mshares 31.47Mshares 2.14M
Pretax incomeUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailable
Diluted EPS$-4.32$-2.56$-32.38
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$24.18M$15.30M$9.71M
Selling & marketingUnavailableUnavailableUnavailable

Balance

ArriVent BioPharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$45.54M$74.29M$150.39M
Total assets$333.17M$274.94M$163.10M
Current assets$332.90M$226.98M$159.97M
Total liabilities$25.94M$17.29M$11.80M
Current liabilities$25.94M$17.27M$11.62M
Total equity incl. NCI$307.22M$257.65M-$153.19M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$5.93M$3.78M$4.53M

Cash flow

ArriVent BioPharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$160.59M-$70.21M-$55.84M
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flow-$71.23M-$192.46MUnavailable
Financing cash flow$203.06M$186.58M$42.86M
Net change in cash-$28.75M-$76.10M-$12.98M
Stock-based compensation$12.52M$3.21M$895.00K
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortization-$3.03MUnavailableUnavailable

Derived

ArriVent BioPharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flowUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio12.83x13.14x13.76x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AVBP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2023-12-31

Difference 304490000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.